Alivus Life Sciences Limited Q3 FY26 results press release summary

Results press release of 22 Jan 2026, summarised by AI from the filing.

Alivus Life Sciences reports record Q3FY26 revenue of ₹6,729 Mn and highest ever EBITDA margin of 36.4%.

Key takeaways

1. FY26 guidance High single-digit revenue growth for FY26 and sustained margin expansion in the current year.
2. CDMO turnaround CDMO business recovered as expected, delivering the turnaround planned for the second half of the year.
3. Non-GPL growth Non-GPL business across Europe, Japan, LATAM, ROW and India grew 16% YoY in 9MFY26, in-line with guidance.
4. CDMO weakness CDMO business had weakened and only recovered in the second half of the year.

Original filing on BSE

Alivus Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹640 cr (+6% year on year), EBITDA ₹212 cr (+23% year on year), PAT ₹160 cr (+31% year on year), EBITDA margin 33.1% (+449 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹689 cr (+6% year on year), EBITDA ₹215 cr (+8% year on year), PAT ₹163 cr (+15% year on year), EBITDA margin 31.1% (+67 bps). Score 48 of 100, In line with trend. EBITDA margin rose 67 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.7% in 29 days (Nifty 500: −0.1%).
• Q3 FY26: Revenue ₹673 cr (+5% year on year), EBITDA ₹231 cr (+22% year on year), PAT ₹150 cr (+21% year on year), EBITDA margin 34.4% (+477 bps). Score 59 of 100, In line with trend. EBITDA margin rose 477 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +11.1% in 29 days (Nifty 500: +2.5%).
• Q2 FY26: Revenue ₹588 cr, EBITDA ₹178 cr, PAT ₹130 cr, EBITDA margin 30.3%. Not scored. No result for the same quarter last year. Share price after the results: −0.8% in 29 days (Nifty 500: +1.4%).
• Q1 FY26: Revenue ₹602 cr, EBITDA ₹172 cr, PAT ₹122 cr, EBITDA margin 28.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.6% in 28 days (Nifty 500: −0.9%).
• Q4 FY25: Revenue ₹650 cr, EBITDA ₹198 cr, PAT ₹142 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year. Share price after the results: −15.9% in 29 days (Nifty 500: +0.5%).
• Q3 FY25: Revenue ₹642 cr, EBITDA ₹190 cr, PAT ₹137 cr, EBITDA margin 29.6%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Alivus Life Sciences Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (31 Jul 2026), Results deck (30 Jul 2026), Results press release (30 Jul 2026)
• Q4 FY26: Earnings call (15 May 2026), Results deck (14 May 2026), Results press release (14 May 2026)
• Q3 FY26: Earnings call (22 Jan 2026), Results deck (22 Jan 2026), Results press release (22 Jan 2026)
• Q2 FY26: Earnings call (7 Nov 2025), Results deck (6 Nov 2025)
• Q1 FY26: Earnings call (2 Aug 2025), Results deck (1 Aug 2025)
• Q4 FY25: Earnings call (16 May 2025), Results deck (15 May 2025), Results press release (15 May 2025)